ClinicalTrials.gg
CompletedNCT04777409EVOKE PlusUpdated Jun 26, 2026

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

A Phase 3 interventional study of Semaglutide and Placebo (semaglutide) in Early Alzheimer´s Disease, sponsored by Novo Nordisk A/S. Completed at 498 sites in 38 countries. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,840
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
37th of 1,609
1,840 · median 73
Started
2021
with 144 others
Phase 3
188 of 1,940
19 open now
Registered
1,298th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 37th largest by enrollment of the 1,609 interventional ones that give a count, is one of 145 that started in 2021, is one of 188 in phase 3, and was the 1,298th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.

Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.

The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken.

Participants must have a study partner, who is willing to take part in the study.

Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period.

A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.

03

Conditions studied

  • Early Alzheimer´s Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 55-85 years (both inclusive) at the time of signing .
  • MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type according to the NIA-AA (National Institute of Aging-Alzheimer's Association) 2018 criteria.
  • CDR (Clinical Dementia Rating) global score of 0.5 and CDR of 0.5 or more in at least one of the three instrumental activities of daily living categories (personal care, home \& hobbies, community affairs) Or CDR global score of 1.0
  • RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) delayed memory index score of below or equal to (≤) 85
  • (Mini-Mental State Examination) greater than or equal to (≥) 22
  • Amyloid positivity established with either amyloid PET (positron emission tomography), CSF (cerebrospinal fluid) Aβ1-42 or CSF Aβ1-42/Aβ1-40.
  • If receiving an approved Alzheimer's disease treatment (such as acetylcholinesterase inhibitors, memantine or aducanumab) the dose must have been stable for at least 3 months prior to screening and should not be changed during the study unless medically necessary.

Exclusion criteria

Exclusion Criteria:

  • Brain Magnetic resonance imaging (MRI) (or Computed Tomography (CT)) scan suggestive of structural CNS (central nervous system) disease confirmed by central read (e.g. cerebral large-vessel disease [large vessel (cortical) infarcts greater than (>) 10 milimeter (mm) in diameter], prior macro-haemorrhage [greater than 1 cubic centimetre (cm\^3)], cerebral vascular malformations, cortical hemosiderosis, intracranial aneurism(s), intracranial tumours, changes suggestive of normal pressure hydrocephalus).
  • Brain MRI (or CT) scan suggestive of strategic infarcts defined as bilateral thalamic lacunar infarcts and singular paramedian thalamic infarcts confirmed by central read.
  • Evidence of a relevant neurological disorder other than mild cognitive impairment (MCI) or mild dementia of the Alzheimer's type at screening, including but not limited to Parkinson's disease, Lewy body disease, frontotemporal dementia of any type, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, systemic lupus erythematosus, progressive supranuclear palsy, neurosyphilis, (HIV), learning disability, intellectual disability, hypoxic cerebral damage, or significant head trauma with loss of consciousness that led to persistent cognitive deficits.
  • Evidence of a clinically relevant or unstable psychiatric disorder, based on (DSM-5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A participant with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or whose depression is controlled with treatment can be included in the study per investigator's judgement.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,840 participants (actual)

Study arms

  • Experimental
    Oral semaglutide

    Participants are given oral semaglutide once daily

    Drug: Semaglutide

  • Placebo comparator
    Placebo (semaglutide)

    Participants are given oral placebo once daily

    Drug: Placebo (semaglutide)

Interventions

  • Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks

  • DrugPlacebo (semaglutide)

    Oral placebo (semaglutide) once-daily. The study will last for up to 173 weeks

06

What researchers measure

Primary outcomes

  1. Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score

    Score on scale (0 to 18) Measures the impact of cognitive decline on daily function using the following six domains commonly affected in Alzheimer's disease: * Cognitive domains: memory, orientation, and judgement and problem solving * Function domains: community affairs, home and hobbies, and personal care Based on clinical information obtained from the subject and informant, an individual box score ranging from 0 to 3 is determined that represents "none" to "severe" impairment for each of the six domains. The CDR-Sum of Boxes (CDR-SB) score will be derived by adding the individual scores of the six domains at a given time point. The total CDR-SB score ranges from 0 to 18 with higher scores representing greater impairment.

    Time frame: From baseline (week 0) to week 104

Secondary outcomes

  1. Main Phase: Change in the 24-item Alzheimer's Disease Cooperative Study Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-ADL-MCI) score

    Score on scale (0 to 53). An interview-based assessment of information provided by the study partner (informant). The total scores based on 18 items on the scale range from 0 to 53 with lower scores representing greater impairment.

    Time frame: From baseline (week 0) to week 104

  2. Extension phase: Change in the ADCS-ADL-MCI score

    Score on scale (0 to 53) An interview-based assessment of information provided by the study partner (informant). The total scores based on 18 items on the scale range from 0 to 53 with lower scores representing greater impairment.

    Time frame: From baseline (week 0) to week 156

  3. Main Phase: Time to progression to Clinical Dementia Rating (CDR) global score greater than or equal to (≥)1.0 among patients with CDR global score equal to (=) 0.5 at baseline

    Week(s)

    Time frame: From baseline (week 0) up to week 156

  4. Extension Phase: Time to progression to Clinical Dementia Rating (CDR) global score greater than or equal to (≥)1.0 among patients with CDR global score equal to (=) 0.5 at baseline

    Week(s)

    Time frame: From baseline (week 0) to week 156

  5. Main Phase: Change in the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog-13) score

    Score on scale (0 to 85) Measures the severity of cognitive impairment in various domains including memory, language, orientation, praxis and executive function. The total scores on the scale range from 0 to 85 with higher scores representing greater impairment.

    Time frame: From baseline (week 0) to week 104

  6. Extension Phase: Change in the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog-13) score

    Score on scale (0 to 85) Measures the severity of cognitive impairment in various domains including memory, language, orientation, praxis and executive function. The total scores on the scale range from 0 to 85 with higher scores representing greater impairment.

    Time frame: From baseline (week 0) to week 156

  7. Main Phase: Change in the Montreal Cognitive Assessment (MoCA) score

    Score on scale (0 to 30) The assessment includes 8 domains of cognitive function with total scores ranging from 0 to 30 and lower scores indicating greater impairment.

    Time frame: From baseline (week 0) to week 104

  8. Extension Phase: Change in the Montreal Cognitive Assessment (MoCA) score

    Score on scale (0 to 30) The assessment includes 8 domains of cognitive function with total scores ranging from 0 to 30 and lower scores indicating greater impairment.

    Time frame: From baseline (week 0) to week 156

  9. Main Phase: Change in the Alzheimer's Disease Composite Score (ADCOMS)

    Score on scale (0 to 1.97) The ADCOMS is a composite clinical outcome comprising 4 items from the ADAS-Cog-13, 2 items from the MMSE and all 6 items from the CDR-SB.32 The total scores on the scale range from 0 to 1.97 with higher scores indicating greater impairment.

    Time frame: From baseline (week 0) to week 104

  10. Extension Phase: Change in the Alzheimer's Disease Composite Score (ADCOMS)

    Score on scale (0 to 1.97) The ADCOMS is a composite clinical outcome comprising 4 items from the ADAS-Cog-13, 2 items from the MMSE and all 6 items from the CDR-SB.32 The total scores on the scale range from 0 to 1.97 with higher scores indicating greater impairment.

    Time frame: From baseline (week 0) to week 156

  11. Main Phase: Change in the Mini-Mental State Examination (MMSE) score

    Score on scale (0 to 30) The MMSE measures orientation, attention, memory, language and visuo-spatial function. The total scores on the scale range from 0 to 30 with lower scores indicating greater impairment.

    Time frame: From baseline (week 0) to week 104

  12. Extension Phase: Change in the Mini-Mental State Examination (MMSE) score

    Score on scale (0 to 30) The MMSE measures orientation, attention, memory, language and visuo-spatial function. The total scores on the scale range from 0 to 30 with lower scores indicating greater impairment.

    Time frame: From baseline (week 0) to week 156

  13. Main Phase: Time to progression in disease stage based on CDR global score

    Week(s)

    Time frame: From baseline (week 0) up to week 156

  14. Extension Phase: Time to progression in disease stage based on CDR global score

    Week(s)

    Time frame: From baseline (week 0) to week 156

  15. Main Phase: Change in the composite Z-score based on the three outcome measures CDR-SB, ADCS-ADL-MCI, and ADAS-Cog-13

    Score

    Time frame: From baseline (week 0) to week 104

  16. Extension Phase: Change in the composite Z-score based on the three outcome measures CDR-SB, ADCS-ADL-MCI, and ADAS-Cog-13

    Score

    Time frame: From baseline (week 0) to week 156

  17. Main Phase: Change in the 10-item Neuropsychiatric Inventory (NPI) score

    104 Score on scale (0 to 120) The 10-item scale assesses symptoms including delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability and aberrant motor activity. For each domain the frequency (4-point scale) and severity (3-point scale) of symptoms is reported. The score for each domain is calculated by multiplying the frequency and severity score. The total 10-item NPI score is 0 to 120 with higher scores indicating a greater symptomatology.

    Time frame: From baseline (week 0) to week 104

  18. Extension Phase: Change in the 10-item Neuropsychiatric Inventory (NPI) score

    104 Score on scale (0 to 120) The 10-item scale assesses symptoms including delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability and aberrant motor activity. For each domain the frequency (4-point scale) and severity (3-point scale) of symptoms is reported. The score for each domain is calculated by multiplying the frequency and severity score. The total 10-item NPI score is 0 to 120 with higher scores indicating a greater symptomatology.

    Time frame: From baseline (week 0) to week 156

  19. Main Phase: Change in high sensitivity C-reactive protein level

    Ratio to baseline

    Time frame: From baseline (week 0) to week 104

  20. Extension Phase: Change in high sensitivity C-reactive protein level

    Ratio to baseline

    Time frame: From baseline (week 0) to week 156

  21. Main Phase: Number of treatment emergent adverse events (TEAEs)

    Number of events

    Time frame: From baseline (week 0) up to week 156

  22. Extension Phase: Number of treatment emergent adverse events (TEAEs)

    Number of events

    Time frame: From baseline (week 0) to week 156

  23. Main Phase: Time to first occurrence of major adverse cardiovascular event (MACE) comprising non-fatal myocardial infarction, non-fatal stroke and allcause death

    Week(s)

    Time frame: From baseline (week 0) to week 104

  24. Extension Phase: Time to first occurrence of major adverse cardiovascular event (MACE) comprising non-fatal myocardial infarction, non-fatal stroke and allcause death

    Week(s)

    Time frame: From baseline (week 0) to week 156

  25. Main Phase: Time to first occurrence of stroke

    Weeks

    Time frame: From baseline (week 0) to week 104

  26. Extension Phase: Time to first occurrence of stroke

    Weeks

    Time frame: From baseline (week 0) to week 156

  27. Main Phase: Change in the EQ-5D-5L (proxy version) index score

    Score The EQ-5D-5L descriptive system comprises mobility, self-care, usual activities, pain/discomfort and anxiety/depression with five response levels each (no problems, slight problems, moderate problems, severe problems, unable to /extreme problems). The EQ-5D-5L proxy version 1 (the study partner is asked to rate how he/she \[the proxy\] would rate the subject´s health) will be used in this trial.

    Time frame: From baseline (week 0) to week 104

  28. Extension Phase: Change in the EQ-5D-5L (proxy version) index score

    Score The EQ-5D-5L descriptive system comprises mobility, self-care, usual activities, pain/discomfort and anxiety/depression with five response levels each (no problems, slight problems, moderate problems, severe problems, unable to /extreme problems). The EQ-5D-5L proxy version 1 (the study partner is asked to rate how he/she \[the proxy\] would rate the subject´s health) will be used in this trial.

    Time frame: From baseline (week 0) to week 156

  29. Extension phase: Change in the CDR-SB score

    Score on scale (0 to 18) Measures the impact of cognitive decline on daily function using the following six domains commonly affected in Alzheimer's disease: * Cognitive domains: memory, orientation, and judgement and problem solving * Function domains: community affairs, home and hobbies, and personal care Based on clinical information obtained from the subject and informant, an individual box score ranging from 0 to 3 is determined that represents "none" to "severe" impairment for each of the six domains. The CDR-Sum of Boxes (CDR-SB) score will be derived by adding the individual scores of the six domains at a given time point. The total CDR-SB score ranges from 0 to 18 with higher scores representing greater impairment.

    Time frame: From baseline (week 0) to week 156

07

Study locations

498 sites
  • Banner Alzheimer's Institute
    Phoenix, Arizona 85006, United States
  • Imaging Endpoints
    Scottsdale, Arizona 85258, United States
  • Banner Sun Health Research Institute
    Sun City, Arizona 85351, United States
  • Tucson Neuroscience Research
    Tucson, Arizona 85710, United States
  • Advanced Research Center, Inc.
    Anaheim, California 92805, United States
  • Torrance Clin Res Inst, Inc.
    Lomita, California 90717, United States
  • ASCLEPES Research Centers,
    Long Beach, California 90807, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • UCLA_Los Angeles
    Los Angeles, California 90095, United States
  • Wr-Pri, Llc
    Newport Beach, California 92660, United States
  • Well Care Medical Center
    Panorama City, California 91402, United States
  • Cedars-Sinai Medical Center
    Pasadena, California 90048, United States
  • Sharp Neurocog Res Ctr
    San Diego, California 92123, United States
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • Calfornia Neurosc Resrch Med
    Sherman Oaks, California 91403, United States
  • Southern California Research LLC
    Simi Valley, California 93065, United States
  • Mountain Neurological Research Center, Inc.
    Basalt, Colorado 81621, United States
  • Denver Neurological Research
    Denver, Colorado 80210, United States
  • Mile High Research Center
    Denver, Colorado 80218, United States
  • Nuvance Health, Associtd Neuro
    Danbury, Connecticut 06810, United States
  • Yale University
    Fairfield, Connecticut 06824, United States
  • Research Center for Clinical Studies, Inc
    Norwalk, Connecticut 06851, United States
  • Topaz Clinical Research
    Apopka, Florida 32703, United States
  • JEM Research Institute
    Atlantis, Florida 33462, United States
  • Visionary Investigators Network
    Aventura, Florida 33180, United States
  • K2 Medical Research - Winter Garden
    Clermont, Florida 34711, United States
  • Brain Matters Research
    Delray Beach, Florida 33445, United States
  • Integrity Clinical Research, LLC
    Doral, Florida 33122, United States
  • Neuropsychiatric Research Cent
    Fort Myers, Florida 33912, United States
  • Finlay Medical Research Group
    Greenacres City, Florida 33467, United States
  • Indago Research & Health Center Inc.
    Hialeah, Florida 33012, United States
  • Hlth Cr Family Rehab & Res Ctr
    Hialeah, Florida 33015, United States
  • Galiz Research
    Hialeah, Florida 33016, United States
  • K2 The Villages
    Lady Lake, Florida 32159, United States
  • K2 Medical Research, Maitland
    Maitland, Florida 32751, United States
  • Hlth Cr Family Rehab & Res Ctr
    Miami, Florida 33015, United States
  • Premier Clin Res Inst, Inc.
    Miami, Florida 33122, United States
  • Premier Clinical Research Institute, Inc.
    Miami, Florida 33122, United States
  • Central Miami Medical Institute
    Miami, Florida 33125, United States
  • Novel Clinical Research Center, LLC
    Miami, Florida 33173, United States
  • IMIC, Inc- Medical Research
    Miami, Florida 33176, United States
  • The Neurology Research Group
    Miami, Florida 33176, United States
  • Visionary Inv Ntwrk_Miami
    Miami, Florida 33176, United States
  • Aqualane Clinical Research
    Naples, Florida 34105, United States
  • Suncoast Clin Res Port Richey
    New Port Richey, Florida 34652, United States
  • Suncoast Clinical Research, Inc._New Port Richey
    New Port Richey, Florida 34652, United States
  • K2 Medical Research - Winter Garden
    Ocoee, Florida 34761, United States
  • Combined Research Orlando Phase I-IV
    Orlando, Florida 32807, United States
  • Headlands Research Orlando
    Orlando, Florida 32819, United States
  • Advanced Research Consultants, Inc.
    Palm Beach Gardens, Florida 33410, United States
  • Intercoastal Medical Group
    Sarasota, Florida 34239, United States
  • The Roskamp Institute, Inc.
    Sarasota, Florida 34243, United States
  • Brain Matters Resrch Kane Cntr
    Stuart, Florida 34997, United States
  • Axiom Clinical Research of Florida
    Tampa, Florida 33609, United States
  • Stedman Clinical Trials LLC
    Tampa, Florida 33613, United States
  • Palm Beach Neuro Premiere Res
    West Palm Beach, Florida 33407, United States
  • Conquest Research
    Winter Park, Florida 32789, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Hawaii Neuroscience, Memory Disorders Center
    Honolulu, Hawaii 96817, United States
  • Velocity Clinical Research, Meridian
    Meridian, Idaho 83642, United States
  • Velocity Clinical Research
    Meridian, Idaho 83642, United States
  • Josephson Wallack Munshower
    Indianapolis, Indiana 46256, United States
  • Cotton-O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • University of Kentucky_Lexington_0
    Lexington, Kentucky 40504, United States
  • Northern Light Eastern Maine Medical Center
    Bangor, Maine 04401, United States
  • ActivMed Practice & Research LLC
    Methuen, Massachusetts 01844, United States
  • Bronson Lakeview Neurobehavioral Health
    Paw Paw, Michigan 49079, United States
  • HealthPartners Center for Memory and Aging
    Saint Paul, Minnesota 55130, United States
  • Hattiesburg Clinic
    Hattiesburg, Mississippi 39401, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • Wr-Crcn, Llc
    Las Vegas, Nevada 89106, United States
  • Patient First MD,clinical Trials
    Middletown, New Jersey 07748, United States
  • Advanced Memory Research Institute of NJ
    Toms River, New Jersey 08755, United States
  • Albuquerque neuroscience Inc
    Albuquerque, New Mexico 87109, United States
  • SPRI Clinical Trials, LLC
    Brooklyn, New York 11235, United States
  • Neurological Assoc Long Island
    Lake Success, New York 11042, United States
  • Feinstein Institute for Medical Research
    Manhasset, New York 11030, United States
  • NYU Grossman School of Med
    New York, New York 10016, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10314, United States
  • SUNY Upstate Medical University_Syracuse
    Syracuse, New York 13210, United States
  • New Hope Clinical Research
    Charlotte, North Carolina 28211, United States
  • AMC Research, LLC
    Matthews, North Carolina 28105, United States
  • NeuroScience Research Center, LLC
    Canton, Ohio 44718, United States
  • Valley Medical Primary Care
    Centerville, Ohio 45459, United States
  • Insight Clinical Trials LLC
    Independence, Ohio 44131, United States
  • Cleveland Clinic_Lakewood
    Lakewood, Ohio 44107, United States
  • Central States Research, LLC
    Tulsa, Oklahoma 74136, United States
  • Summit Research Network Oregon Inc.
    Portland, Oregon 97210, United States
  • Neural Net Research, LLC
    Portland, Oregon 97225, United States
  • The Clinical Trial Center
    Jenkintown, Pennsylvania 19046, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Lowcountry Center for Vet Res
    Charleston, South Carolina 29403, United States
  • Coastal Neurology
    Port Royal, South Carolina 29935, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Genesis Neuroscience Clinic
    Knoxville, Tennessee 37909, United States
  • Vanderbilt Medical Center
    Nashville, Tennessee 37212, United States
  • Texas Diabetes & Endocrinology
    Austin, Texas 78749, United States
  • Neurology Consultants of Dallas
    Dallas, Texas 75243, United States
  • Balyor College of Medicine
    Houston, Texas 77030, United States
  • Univ Of Texas Hlth Science Cntr
    Houston, Texas 77054, United States

Showing the first 100 of 498 sites across 38 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Cummings JL, Atri A, Sano M, Zetterberg H, Scheltens P, Knop FK, Johannsen P, Wichmann CA, Abschneider RM, Leon T, Feldman HH. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. 2026 May 30;407(10544):2167-2179. doi: 10.1016/S0140-6736(26)00459-9. Epub 2026 Mar 19. PubMed 41865758 ↗
  • Scheltens P, Atri A, Feldman HH, Zetterberg H, Sano M, Johannsen P, Colombo TL, Bardtrum L, Jeppesen R, Hansen CT, Cummings JL. Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease. Alzheimers Dement (N Y). 2026 Jan 10;12(1):e70200. doi: 10.1002/trc2.70200. eCollection 2026 Jan-Mar. PubMed 41522368 ↗
  • Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, Johannsen P, Leon T, Scheltens P. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease. Alzheimers Res Ther. 2025 Jan 8;17(1):14. doi: 10.1186/s13195-024-01666-7. PubMed 39780249 ↗
  • van Sloten TT, Luchsinger JA, Launer LJ, Strachan M, Cukierman-Yaffe T, Gerstein HC, Sattar N, Biessels GJ. Call for effective therapies for preventing dementia in people with type 2 diabetes. Lancet Diabetes Endocrinol. 2024 Aug;12(8):510-513. doi: 10.1016/S2213-8587(24)00158-X. Epub 2024 Jun 17. No abstract available. PubMed 38901446 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Sep 2025, 51 months.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 51 months is above that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Mar 2, 2021
StartActual
May 18, 2021
Primary completionActual
Sep 15, 2025
CompletionActual
Jan 30, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04777409
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 2, 2021
Start date
May 18, 2021
Primary completion
Sep 15, 2025
Completion
Jan 30, 2026
Last update
Jun 26, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion